JPRN-UMIN000030609CompletedPhase 2
Assessment of the safety of long-term nicotinamide mononucleotide (NMN) in healthy subjects; phase II study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims. - Assessment of the safety of long-term nicotinamide mononucleotide (NMN).
Keio University School of Medicine0 sites13 target enrollmentStarted: December 29, 2017Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 13
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 40years-old to 60years-old (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1 the subjects with a previous history of diseases. 2 the subjects with malignant neoplasms. 3 the subjects with serious infections. 4 the subjects with psychiatric disorders. 5 the subjects with ophthalmic disorder. 6 the subjects with allergic disorders. 7 the subjects who are regarded as inadequate by the investigator. 8 the subjects who have obvious abnormality in the screening test
Investigators
Similar Trials
Completed
Phase 1
Assessment of the safety of nicotinamide mononucleotide (NMN) in healthy subjects; phase I study. The clinical trial to evaluate metabolic-syndrome-related parameters to develop NMN as Foods with Function Claims.healthy subjectsJPRN-UMIN000021309Keio University School of Medicine10
Recruiting
Phase 1
Pilot study of safety and efficacy of nicotinamide (vitamin B3) in OPA1 Dominant Optic Atrophy -NICOPA1-TODominant Optic AtrophyCTIS2023-506214-52-00Centre Hospitalier Universitaire D Angers25
Active, not recruiting
Phase 1
Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with elevated phosphat levelDialysis-dependent patients with hyperphosphatemiaMedDRA version: 17.0Level: LLTClassification code 10020712Term: HyperphosphatemiaSystem Organ Class: 100000004861EUCTR2013-000488-95-PLMEDICE Arzneimittel Pütter GmbH & Co. KG700
Active, not recruiting
Phase 1
Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with elevated phosphat levelDialysis-dependent patients with hyperphosphatemiaMedDRA version: 19.0Level: LLTClassification code 10020712Term: HyperphosphatemiaSystem Organ Class: 100000004861EUCTR2013-000488-95-ATMEDICE Arzneimittel Pütter GmbH & Co. KG700
Active, not recruiting
Not Applicable
Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with elevated phosphat levelEUCTR2013-000488-95-HUMEDICE Arzneimittel Pütter GmbH & Co. KG700